The estimated Net Worth of Ankur Dhingra is at least 10.1 百万$ dollars as of 26 March 2024. Mr Dhingra owns over 100,000 units of Caredx Inc stock worth over 10,126,952$ and over the last 4 years he sold CDNA stock worth over 0$.
Mr has made over 5 trades of the Caredx Inc stock since 2021, according to the Form 4 filled with the SEC. Most recently he bought 100,000 units of CDNA stock worth 375,000$ on 26 March 2024.
The largest trade he's ever made was buying 196,362 units of Caredx Inc stock on 7 March 2023 worth over 206,180$. On average, Mr trades about 35,798 units every 85 days since 2021. As of 26 March 2024 he still owns at least 354,958 units of Caredx Inc stock.
You can see the complete history of Mr Dhingra stock trades at the bottom of the page.
Ankur Dhingra is the Chief Financial Officer at Caredx Inc.
Mr Dhingra is 45, he's been the Chief Financial Officer of Caredx Inc since . There are 12 older and 2 younger executives at Caredx Inc. The oldest executive at Caredx Inc is Ralph Snyderman, 80, who is the Independent Director.
Ankur's mailing address filed with the SEC is 5200 ILLUMINA WAY, , SAN DIEGO, CA, 92122.
Over the last 10 years, insiders at Caredx Inc have traded over 60,271,359$ worth of Caredx Inc stock and bought 1,726,634 units worth 9,072,700$ . The most active insiders traders include Group Holdings (Sbs) Adviso...、Neil Gagnon、Peter Maag. On average, Caredx Inc executives and independent directors trade stock every 17 days with the average trade being worth of 615,506$. The most recent stock trade was executed by Alexander L Johnson on 20 August 2024, trading 61,023 units of CDNA stock currently worth 1,432,820$.
caredx: transforming transplant patient care through novel surveillance management solutions caredx, inc. is dedicated to improving the lives of organ transplant patients through non-invasive diagnostics. by combining the latest advances in genomics and bioinformatics technology, with a commitment to generating high quality clinical evidence through trials and registries, caredx is at the forefront of organ transplant surveillance and pre-transplant hla typing solutions. nasdaq:cdna about allosure® allosure is the first and only non-invasive blood test that directly measures allograft injury and identifies the probability of active rejection to better manage kidney transplant patients. allosure is a clinical-grade, proprietary next-generation sequencing (ngs) based test to detect donor-derived cell-free dna (dd-cfdna) in order to identify organ injury in kidney transplant recipients. allosure is analytically validated as a sensitive, specific, and precise measurement of dd-cfdna. allos
Caredx Inc executives and other stock owners filed with the SEC include: